Investors Can Step Up in Ultragenyx Securities Fraud Class Action Lawsuit

In a significant development for shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), the Rosen Law Firm, a prominent global firm specializing in investor rights, has called on buyers of the company’s common stock from August 3, 2023, to December 26, 2025, to consider stepping forward in a class action lawsuit. The deadline for potential lead plaintiffs is set for April 6, 2026. Here’s what investors need to know.

The Opportunity

If you purchased shares of Ultragenyx during the specified class period, you may be entitled to financial compensation without incurring any out-of-pocket expenses, given that the firm operates on a contingency fee basis. This means that you pay no fees unless the class action is successful in securing damages for investors.

For those interested, the first step is to either submit a form online or contact Phillip Kim, Esq. at 866-767-3653 for additional information regarding participation in the class action.

Background of the Lawsuit

The lawsuit alleges that the executives at Ultragenyx misled investors by issuing overly optimistic assessments regarding the company's drug developments. Specifically, the claims involve material misstatements about the expected outcomes from the Phase III Orbit and Cosmic Studies that tested a treatment known as setrusumab, aimed at patients suffering from Osteogenesis Imperfecta (OI).

Misleading Statements

The defendants purportedly communicated confidence about setrusumab's ability to effectively reduce the annualized fracture rates in OI patients while simultaneously concealing adverse information regarding the drug’s actual effectiveness. Reports suggest that while setrusumab may enhance material bone density, this increase does not correlate to an actual reduction in fractures. Furthermore, it was indicated that the clinical studies were unlikely to support the management's claims about the treatment's efficacy.

As a result of these misleading statements and the withholding of crucial information, many investors bought Ultragenyx's securities at artificially inflated prices, leading to significant financial damages once the true facts emerged.

Importance of Selecting Qualified Counsel

Rosen Law Firm strongly encourages investors to select qualified legal representation with a proven track record in leading roles within securities class action lawsuits. Many firms may issue notices about lawsuits without possessing comparable experience or resources. Investors must be judicious in their choice of counsel to ensure their interests are adequately protected.

The Rosen Law Firm's Achievements

The Rosen Law Firm has established itself as a leader in the realm of securities class actions and has garnered extensive recognition for its results. The firm has achieved notable settlements for clients, including the largest ever securities class action settlement against a Chinese firm. Since 2013, it has consistently ranked among the top firms for securing litigated settlements in this arena and was honored for recovering tens of millions of dollars for investors in 2019 alone. Given its reputation, investors are encouraged to consult with the firm for guidance.

Next Steps for Investors

If you are an investor seeking to join this class action lawsuit, be informed that no class has yet been certified. Until certification is achieved, you are not officially represented by legal counsel unless you select one of your own choosing. You have the option to remain an absent class member and take no further action at this time, although your eligibility for any potential recovery will not hinge on serving as a lead plaintiff.

For ongoing updates about the case and the Rosen Law Firm’s initiatives, connect with them through their LinkedIn, Twitter, and Facebook pages.

Conclusion

For Ultragenyx investors, this class action represents a crucial opportunity to seek justice and potentially reclaim losses incurred as a result of alleged fraudulent practices. Timely action prior to the April 6, 2026 deadline is essential for those wishing to lead in the litigation process. This is a pivotal moment for affected shareholders, and being informed can make a significant difference in their legal journey.